• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Asthma COPD Drugs Companies

    ID: MRFR/Pharma/7277-CR
    149 Pages
    Rahul Gotadki
    July 2025

    Asthma and Chronic Obstructive Pulmonary Disease (COPD) are chronic respiratory conditions, and several pharmaceutical companies are actively involved in the research, development, and manufacturing of drugs to manage and treat these conditions.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Asthma COPD Drugs Market

    Asthma and COPD Drugs Key Companies

     


    Latest Asthma and COPD Drugs Companies Update:

    GlaxoSmithKline (GSK) Presented positive Phase 3 data for their investigational IL-5 inhibitor, BEZP1144, demonstrating significant improvements in lung function and reduction in exacerbations for severe asthma patients.


    AstraZeneca Received FDA approval for the first generic version of Symbicort, opening up cost-effective treatment options for patients.


    Viatris and Kindeva Drug Delivery Launched Breyna, a budesonide-formoterol combination inhaler for asthma and COPD, targeting patients above six years old.


    Novartis Announced expansion of clinical trials for their IL-17/IL-17A inhibitor, QGE003, to include patients with moderate-to-severe COPD.


    Roche Collaborated with Lung Foundation Australia to develop and implement a digital platform for self-management of chronic respiratory diseases like asthma and COPD.


    List of Asthma and COPD Drugs Key companies in the market

    • Teva Pharmaceutical Industries Ltd (Israel)

    • GSK plc (UK)

    • Merck& Co., Inc (US)

    • Hoffmann-La Roche Ltd (Switzerland)

    • AstraZeneca (UK)

    • Boehringer Ingelheim International GmbH (Germany)

    • Sanofi (France)

    • Koninklijke Philips N.V. (Netherlands)

    • BD (US)

    • Sunovion Pharmaceuticals, Inc (US)